Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Roche Holding AG (ROG.SW)

Swiss - Swiss Delayed Price. Currency in CHF
Add to watchlist
358.60-3.45 (-0.95%)
At close: 5:31PM CET
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close362.05
Open356.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range355.35 - 362.00
52 Week Range293.05 - 378.95
Volume1,125,058
Avg. Volume1,106,362
Market Cap310.274B
Beta (5Y Monthly)0.28
PE Ratio (TTM)22.08
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield9.10 (2.54%)
Ex-Dividend DateMar 18, 2021
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for ROG.SW

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    All
    News
    • GlobeNewswire

      Roche Extraordinary General Meeting 2021

      All proposals of the Board of Directors approved Audited statutory interim financial statements (standalone financial statements) of the Company as of 31 October 2021 approved Share capital reduction by cancellation of 53,309,000 bearer shares with a nominal value of CHF 1 each approved Basel, 26 November 2021 – On 4 November 2021, Roche (SIX: RO, ROG; OTCQX: RHHBY) had announced its agreement with Novartis Holding AG (Novartis) regarding the repurchase of the equity stake held by Novartis in Ro

    • Business Wire

      Genentech to Present New Pivotal Data at ASH 2021 From Broad and Comprehensive Portfolio, Challenging Treatment Standards for People With Blood Disorders

      SOUTH SAN FRANCISCO, Calif., November 23, 2021--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its extensive hematology portfolio will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition from December 11-14, 2021. Genentech molecules will be featured in more than 90 abstracts, including 17 oral presentations, showcasing new immunotherapies, unique treatment combinations, the application of novel endpoints,

    • GlobeNewswire

      Roche to present new pivotal data at ASH 2021 from broad and comprehensive portfolio, challenging treatment standards for people with blood disorders

      Phase III POLARIX trial showed Polivy plus R-CHP was the first treatment in two decades to significantly improve outcomes in newly diagnosed diffuse large B-cell lymphoma (DLBCL) versus the standard of care1Pivotal data on mosunetuzumab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, showed high response rates in relapsed or refractory follicular lymphoma (FL)2HAVEN 6 phase III interim data demonstrated Hemlibra’s favourable safety and efficacy profile in people with mo

    Advertisement
    Advertisement